Neovascular-targeted immunoconjugates

Details Neovascular-targeted immunoconjugates Neovascular-targeted immunoconjugates

2010-12-23

2011-12-06

Yu, Misook (Department: 1643)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugate includes potentiator; or composition comprising...

C424S178100, C530S384000, C530S387100, C530S387300, C530S391700

Reexamination Certificate

active

08071104

ABSTRACT:
Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

REFERENCES:
patent: 4752569 (1988-06-01), Terasaki et al.
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4865998 (1989-09-01), Feickert et al.
patent: 4959318 (1990-09-01), Foster et al.
patent: 4997762 (1991-03-01), Hanna, Jr. et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5428130 (1995-06-01), Capon et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5759808 (1998-06-01), Casterman et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5800988 (1998-09-01), Casterman et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5840526 (1998-11-01), Casterman et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5879672 (1999-03-01), Davis et al.
patent: 5939530 (1999-08-01), Gelboin et al.
patent: 5969107 (1999-10-01), Carceller et al.
patent: 5981471 (1999-11-01), Papathanassiu et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6005079 (1999-12-01), Casterman et al.
patent: 6015695 (2000-01-01), Casterman et al.
patent: 6017514 (2000-01-01), Epstein et al.
patent: 6039944 (2000-03-01), Berkner et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6140470 (2000-10-01), Garen et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 6448071 (2002-09-01), Schneck et al.
patent: 6541610 (2003-04-01), Smith
patent: 6555319 (2003-04-01), Wong et al.
patent: 6572852 (2003-06-01), Smith et al.
patent: 7858092 (2010-12-01), Garen et al.
patent: 7887809 (2011-02-01), Garen et al.
patent: 90/14430 (1990-11-01), None
patent: 93/17715 (1993-09-01), None
patent: 94/26787 (1994-11-01), None
patent: 96/01653 (1996-01-01), None
patent: 98/31394 (1998-07-01), None
Gewolb. J. “New Cancer Therapy Kills Blood Vessels.” Science on Line, Oct. 1, 2001. http://www.iconictherapeutics.com/SCIENCE01.pdf.
“Molecule May Kill Cancer Tumors.” The Associate Press, Oct. 1, 2001. http://www.iconictherapeutics.com/APx01.pdf.
Schubert, Charlotte. “Meddling in macular degeneration,”Nature Medicine, Apr. 2003. vol. 9, No. 4, p. 396.
Kimura et al. “The Potential of Active Drug Targeting with Immunoconjugates to Choroidal Neovascularization”, IOVS, vol. 41, No. 4, Mar. 15, 2000, p. S180.
Cruse et al. Illustrated Dictionary of Immunology, CRC Press, p. 109, 1995.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Lederman et al. Molecular Immunology 28: 1171-1181, 1991.
Li et al. Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Coleman P.M. Research in Immunology, 145:33-36, 1994.
E. Wilmes et al., “Versuche zur Herstellung menschlicher monoklonaler Antikorper gegen Melanome unter Verwendung zervikaler Lymphknoten,” Laryng. Rhinol. Otol., (1987), vol. 66, pp. 144-148.
Jamie K. Scott and George Smith, “Searching for Peptide Ligands with an Epitope Library,” Science, (Jul. 27, 1990), vol. 249, pp. 386-390.
James D. Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,” J. Med Biol., (1991), vol. 222, pp. 581-597.
Greg Winter and Cesar Milstein, “Man-made Antibodies,” Nature, (Jan. 24, 1991), vol. 349, pp. 293-299.
James D. Marks et al., By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling, Bio/Technology, (Jul. 1992), vol. 10, pp. 779-783.
G. Del Bino et al., “Apoptotic Cell Death Triggered by Camptothecin or Tenipos.de. The Cell Cycle Specificity and Effects of Ionizing Radiation,” Cell Prolif., (1992), vol. 25, pp. 537-548.
Andrew D. Griffiths et al., “Human Anti-self Antibodies with High Specificity from Phage Display Libraries,” The EMBO Journal, (1993), vol. 12, No. 2, pp. 725-734.
Lee H. Pai and Ira Pastan, “Immunotoxin Therapy for Cancer,” JAMA, (Jan. 6, 1993), vol. 269, No. 1, pp. 78-81.
Dave S.B. Hoon et al., “Molecular Cloning of a Human Monoclonal Antibody Reactive to Ganglioside Antigen on Human Cancers,” Cancer Research, (Nov. 1, 1993), vol. 53, pp. 5244-5250.
Maria-Ana Ghetie and Ellen S. Vitetta, “Recent Developments in ImmunotoxinTherapy,” Current Opinion in Immunology, (1994), vol. 6, pp. 707-714.
Brenda L. Hall et al., “Establishment, Molecular Rescue, and Expression of 123AV16-1, a Tumor-reactive Human Monoclonal Antibody,” Cancer Research, (1994), vol. 54, pp. 5178-5185.
Xiaohong Cai and Alan Garen, “Anti-melanoma Antibodies from Melanoma Patients Immunized with Genetically Modified Autologous tumor cells: Selection of Specific Antibodies from Single-Chain Fv Phage Fusion Libraries,”Proc. Natl. Acad. Sci. USA, (1995), vol. 92, pp. 6537-6541.
Martin Friedlander et al., “Involvement of Integrins αvβ3 and αvβ5 in Ocular Neovascular Diseases,” Proc. Natl. Acad. Sci. USA, (Sep. 1996), vol. 93, pp. 9764-9769.
Xiaohong Cai and Alan Garen, “A Melanoma-Specific VH Antibody Cloned from a Fusion Phage Library of a Vaccinated Melanoma Patient,” Proc. Natl. Acad. Sci. USA, (Jun. 1996), vol. 93, pp. 6280-6285.
Craig D. Dickinson, “Identification of Surface Residues Mediating Tissue Factor Binding and Catalytic Function of the Serine Protease Factor Vlla”, Proc. Natl. Acad. Sci USA, (Dec. 1996), vol. 93, pp. 14379-14384.
Xiaohong Cai and Alan Garen, “Comparison of Fusion Phage Libraries Displaying VH or Single-chain Fv Antibody Fragments Derived from the Antibody Reportoire of a Vaccinated Melanoma Patient as a Source of Melanoma-Specific Targeting Molecules,” Proc. Natl. Acad. Sci. USA, (Aug. 1997), vol. 94, pp. 9261-9266.
Hennie R. Hoogenboom, “Designing and Optimizing Library Selection Strategies for Generating High-affinity Antibodies,” Tibtech, (Feb. 1997), vol. 15, pp. 62-70.
Baiyang Wang, et al, “Human Single-chain Fv Immunoconjugates Targeted to a Melanoma-associated Chondroitin Sulfate Proteoglycan Mediate Specific Lysis of Human Melanoma Cells by Natural Killer Cells and Complement,” Proc. Natl. Acad. Sci. USA, (Feb. 1999), vol. 96, pp. 1627-1632.
Dj Chaplin and Gj Dougherty, “Tumour Vasculature as a Target for Cancer Therapy,” British Journal of Cancer, (1999), vol. 80 (Supplement 1), pp. 57-64.
Zoltan Szekanecz et al., “Angiogenesis in Rheumatoid Arthritis: Pathogenic and Clinical Significance,” J Investig. Med., (1998), vol. 46, pp. 27-41.
Gary S. Firestein, “Starving the Synovium: Angiogenesis and Inflammation in Rheumatoid Arthritis,” The Journal of Clinical Investigation, (Jan. 1999), vol. 103, No. 1, pp. 3-4.
Chris M. Storgard et al., “Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an αvβ3 Antagonist,” The Journal of Clinical Investigation, (1999),

Affiliated with

Also associated with

Rating

Neovascular-targeted immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neovascular-targeted immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neovascular-targeted immunoconjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4307668